4 ms·
The drug there was off-patent. The issue was there was so little money in selling it that it wasn't worth going through the bio-equivalence studies to sell the
by Moshe_Silnorin 11y ago
The drug there was off-patent. The issue was there was so little money in selling it that it wasn't worth going through the bio-equivalence studies to sell the generic, which costs millions, as one would be immediately undercut by the incumbent.